Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort

Open access
Hoffmann-Vold, Anna-Maria, Fretheim, Håvard, Halse, Anne-Kristine, Seip, Marit, Bitter, Helle, Wallenius, Marianne, Garen, Torhild, Salberg, Anne, Brunborg, Cathrine, Midtvedt, Øyvind, Lund, May Brit, Aaløkken, Trond M., Molberg, Øyvind·2019·American Journal of Respiratory and Critical Care Medicine

Abstract

Abstract Rationale Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, population-based data on its overall impact, limiting opportunities for screening and management strategies. Objectives Evaluate impact of ILD in a unique, nationwide, population-based SSc cohort. Methods ILD was assessed prospectively in the Norwegian SSc (Nor-SSc) cohort, including all 815 patients with SSc resident in the country from 2000 to 2012. Lung high-resolution computed tomography (HRCT) scans were available for fibrosis quantification at baseline (n = 650, 80%) and follow-up. Pulmonary function tests were assessed at baseline (n = 703, 86%) and follow-up. Vital status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 incident Nor-SSc cases and 15 individually matched control subjects. Cumulative survival rates were computed. Measurements and Main Results At baseline, 50% of the subjects with SSc (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progression. Mortality correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with greater than 25% fibrosis. SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%. In patients with normal-range baseline FVC (80–100%), the 5- and 10-year survival rates correlated with presence or absence of lung fibrosis, being 83% and 80%, respectively, with no fibrosis and 69% and 56%, respectively, with lung fibrosis (P = 0.03). Conclusions The mere presence of ILD at baseline appears to affect outcome in SSc, suggesting that all patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagnose ILD early and tailor further management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201903-0486oc

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 257

Metadata

Authors
Hoffmann-Vold, A.-M., Fretheim, H., Halse, A.-K., Seip, M., Bitter, H., Wallenius, M., Garen, T., Salberg, A., Brunborg, C., Midtvedt, Ø., Lund, M. B., Aaløkken, T. M., & Molberg, Ø.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2019-11-15
Volume
200
Issue
10
Pages
1258-1266
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2958111965
Cited by
257
References
41
FWCI
16.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. https://app.cochat.ai/papers/10.1164/rccm.201903-0486oc
The paper
Hoffmann-Vold, A.-M., Fretheim, H., Halse, A.-K., Seip, M., Bitter, H., Wallenius, M., Garen, T., Salberg, A., Brunborg, C., Midtvedt, Ø., Lund, M. B., Aaløkken, T. M., & Molberg, Ø. (2019). Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201903-0486oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.